AXIN1 and hepatocellular carcinoma: Tankyrase inhibitors (e.g., XAV939, IWR-1, G007-LK) have shown potential by stabilizing substrates like Axin1/2 and suppressing hyperactive Wnt/β-catenin signaling [19,62], frequently observed in colorectal cancer and hepatocellular carcinoma [63,64,65,66].